IN2012DN03428A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03428A
IN2012DN03428A IN3428DEN2012A IN2012DN03428A IN 2012DN03428 A IN2012DN03428 A IN 2012DN03428A IN 3428DEN2012 A IN3428DEN2012 A IN 3428DEN2012A IN 2012DN03428 A IN2012DN03428 A IN 2012DN03428A
Authority
IN
India
Prior art keywords
pharmaceutical compositions
nitrites
compositions
prodrugs
formulated
Prior art date
Application number
Inventor
Christopher Kevil
Anthony Giordano
Douglas R Flanagan
Panayiotis P Constantinides
Original Assignee
Theravasc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravasc Inc filed Critical Theravasc Inc
Publication of IN2012DN03428A publication Critical patent/IN2012DN03428A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites  or any pharmaceutically acceptable salts  solvates  or prodrugs thereof  and the medical use of these compositions. The pharmaceutical compositions  which can be formulated for oral administration  can provide immediate release or extended release of the nitrite ion (NO2'). The pharmaceutical compositions of the invention are useful  for example  for the treatment of chronic tissue ischemia.
IN3428DEN2012 2009-10-14 2010-10-14 IN2012DN03428A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25148309P 2009-10-14 2009-10-14
PCT/US2010/052683 WO2011047161A1 (en) 2009-10-14 2010-10-14 Pharmaceutical formulations of nitrite and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN03428A true IN2012DN03428A (en) 2015-10-23

Family

ID=43855036

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3428DEN2012 IN2012DN03428A (en) 2009-10-14 2010-10-14

Country Status (10)

Country Link
US (4) US10463689B2 (en)
EP (1) EP2488035B1 (en)
JP (3) JP5758904B2 (en)
CN (2) CN102686111A (en)
AU (1) AU2010306755B2 (en)
CA (1) CA2777066C (en)
ES (1) ES2633618T3 (en)
IL (1) IL219155A0 (en)
IN (1) IN2012DN03428A (en)
WO (1) WO2011047161A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2219657A4 (en) 2007-11-15 2020-01-08 Louisiana State University Use of nitrite salts in chronic ischemia
WO2010147742A2 (en) 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
CA2777066C (en) 2009-10-14 2020-02-18 TheraVasc, LLC Pharmaceutical formulations of nitrite and uses thereof
AU2012296358B2 (en) * 2011-08-17 2016-04-21 Board Of Regents, The University Of Texas System Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
US8627204B2 (en) * 2011-10-18 2014-01-07 Microsoft Corporation Custom optimization of web pages
JP2016509030A (en) 2013-02-20 2016-03-24 セラバスク インコーポレーテッド Nitrite pharmaceutical formulations and their use
EP2994165A4 (en) * 2013-05-10 2017-01-04 Nitromega Corp. Nutritional or dietary supplements containing fatty acids and nitrite
GB201309092D0 (en) * 2013-05-20 2013-07-03 Edixomed Ltd Transdermal delivery system
WO2017214157A1 (en) 2016-06-06 2017-12-14 Theravasc Inc. Pharmaceutical formulations of nitrite uses thereof
AU2018220635A1 (en) * 2017-02-20 2019-08-15 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hydrogen sulfide and/or nitrite in the treatment and prevention of Atrial Fibrillation
US11850271B1 (en) * 2023-05-16 2023-12-26 King Faisal University Topical skin cream

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914446A (en) * 1958-06-26 1959-11-24 Upjohn Co Nitrite stabilized ascorbic acid-cyanocobalamin compositions
US4650484A (en) * 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) * 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) * 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) * 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
WO2000003725A1 (en) 1998-07-14 2000-01-27 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
PT1146862E (en) 1999-01-29 2003-09-30 Disphar Int Bv PHARMACEUTICAL COMPOSITIONS
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
US6314956B1 (en) 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
GB0119011D0 (en) * 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
WO2003051341A1 (en) 2001-12-18 2003-06-26 Alza Corporation Dosage form for providing time-varying patterns of drug delivery
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
WO2003078437A1 (en) * 2002-03-20 2003-09-25 The University Of Queensland Methods and compositions comprising nitric oxide donors and opioid analgesics
CA2379211A1 (en) * 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal The use of methylene blue to reverse the excessive hemodynamic reaction induced by the combination of a nitrocompound and sildenafil or of a molecule of the same class (phosphodiesterase inhibitor)
US9675637B2 (en) * 2003-07-09 2017-06-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
EP1670459A4 (en) * 2003-08-20 2009-03-25 Nitromed Inc Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20050113409A1 (en) 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
PL1846058T3 (en) 2005-02-11 2009-12-31 Nolabs Ab Device method, and use for treatment of neuropathy involving nitric oxide
BRPI0610180A2 (en) 2005-05-24 2012-09-25 Wellgen Inc methods for preventing, treating, and treating or controlling a condition associated with inflammation
SG10201700744YA (en) * 2006-02-10 2017-03-30 Mannatech Inc All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
WO2007149520A2 (en) 2006-06-21 2007-12-27 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
CN101622005B (en) * 2007-02-26 2013-06-05 哈特比特有限公司 New use of nitrites and nitrates and compositions containing these
EP2124638B1 (en) 2007-02-26 2016-12-07 HeartBeet Ltd. Performance enhancing composition and use thereof
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
JP5592790B2 (en) * 2007-08-06 2014-09-17 トリニティ ラボラトリーズ インコーポレイテッド Pharmaceutical composition for treating pain associated with chronic pain and neuropathy
EP2219657A4 (en) 2007-11-15 2020-01-08 Louisiana State University Use of nitrite salts in chronic ischemia
JP2011507968A (en) * 2007-12-27 2011-03-10 エイヤーズ ファーマシューティカルズ、インク． Aerosolized nitrites and nitric oxide donating compounds and their use
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) * 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
WO2010147742A2 (en) 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
US20130209584A1 (en) 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
CA2777066C (en) 2009-10-14 2020-02-18 TheraVasc, LLC Pharmaceutical formulations of nitrite and uses thereof
US20140127329A1 (en) 2011-03-31 2014-05-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
WO2012142413A2 (en) 2011-04-14 2012-10-18 Theravasc Inc. Nitrite compositions and uses thereof
US9294956B2 (en) 2011-12-29 2016-03-22 Qualcomm Incorporated Application-server-assisted preemptive multicast bearer establishment for real-time low-latency applications

Also Published As

Publication number Publication date
EP2488035B1 (en) 2017-04-26
US20200085861A1 (en) 2020-03-19
US20110086069A1 (en) 2011-04-14
JP2013508289A (en) 2013-03-07
JP6125567B2 (en) 2017-05-10
WO2011047161A1 (en) 2011-04-21
US10463689B2 (en) 2019-11-05
US20160067279A1 (en) 2016-03-10
US10307441B2 (en) 2019-06-04
EP2488035A4 (en) 2013-07-31
EP2488035A1 (en) 2012-08-22
CA2777066A1 (en) 2011-04-21
IL219155A0 (en) 2012-06-28
US20200297756A1 (en) 2020-09-24
JP2017141275A (en) 2017-08-17
AU2010306755A1 (en) 2012-05-03
CN107260756A (en) 2017-10-20
CA2777066C (en) 2020-02-18
ES2633618T3 (en) 2017-09-22
JP5758904B2 (en) 2015-08-05
JP2015180674A (en) 2015-10-15
CN102686111A (en) 2012-09-19
AU2010306755B2 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
IN2012DN03428A (en)
UA105911C2 (en) Sulfonamide derivatives
MX2011008634A (en) Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy.
NZ708593A (en) Novel pyrazole derivative
GEP20125459B (en) Compounds for inhibiting mitotic progression
MX341212B (en) Benzodiazepine bromodomain inhibitor.
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
IN2012DN01233A (en)
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EA200971115A1 (en) NEW HIV REVERSE TRANSCRIPTASE INHIBITORS
JO3032B1 (en) Spiro-oxindole compounds and their use as therapeutic agents
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
CL2011000504A1 (en) Compounds derived from pyridin-4-yl-thiazol-2-amide 2-amide-pyrrolidin-1,2-dicarboxylic, phosphatidyl-inositol-3 kinase inhibitors; pharmaceutical composition comprising one of the compounds; and use of the compounds in the preparation of a medicament for the treatment of cancer.
MX2009014235A (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy.
UA105556C2 (en) Combination of compounds comprising hiv integrase inhibitors with other therapeutical agents
MX2010006241A (en) Aminotriazole derivatives as alx agonists.
MX2010009739A (en) Pim kinase inhibitors and methods of their use.
MX2010014234A (en) Pyrazole compounds 436.
MX2011011136A (en) Diaryl ethers.
MX2014000130A (en) Methods and compositions for inhibition of bone resorption.
PH12013500695A1 (en) Pharmaceutical compositions containing a dgat1 inhibitor
MX2009011281A (en) Benzimidazoles and pharmaceutical compositions thereof.
MX2009004017A (en) The uses of the carboxy-amido-triazole compounds and salts thereof.
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions